Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Labs

This article was originally published in The Gray Sheet

Executive Summary

Nov. 23-24 hearing is scheduled in Chicago federal court on plaintiff's motion for a preliminary injunction against Alza Corp. and Abbott Laboratories to block the proposed merger pending dissemination to Alza shareholders the facts concerning the status of Abbott's negotiations with FDA on manufacturing deficiencies at Abbott's Lake County, Illinois facilities, Abbott reports Oct. 28. Abbott announced continuing difficulties with FDA on Sept. 28 (1"The Gray Sheet" Oct. 4, p. 16), seven days after Alza shareholders approved the merger

You may also be interested in...

Abbott Facing FDA Consent Decree Over Alleged QSR Violations

Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts